Plant Name: Salix matsudana
Taxonomic Information:
Plant ID: NPO22503
Plant Latin Name: Salix matsudana
Taxonomy Genus: Salix
Taxonomy Family: Salicaceae
Plant External Links:
NCBI TaxonomyDB:
349989
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Unknown.
Geographical Distribution:
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| NR1H4; | |
| MAOA; | |
| AKR1B10; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0008131; primary amine oxidase activity | 1.242E-03 | 6.289E-01 | MAOA |
| MF | GO:0003824; catalytic activity | GO:0001758; retinal dehydrogenase activity | 1.449E-03 | 6.713E-01 | AKR1B10 |
| MF | GO:0060089; molecular transducer activity | GO:0004887; thyroid hormone receptor activity | 1.449E-03 | 6.713E-01 | NR1H4 |
| MF | GO:0005488; binding | GO:0046965; retinoid X receptor binding | 3.103E-03 | 9.255E-01 | NR1H4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00340 | Histidine metabolism | 4.792E-03 | 1.793E-02 | MAOA |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00360 | Phenylalanine metabolism | 3.396E-03 | 1.793E-02 | MAOA |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00350 | Tyrosine metabolism | 6.982E-03 | 1.793E-02 | MAOA |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 7.181E-03 | 1.793E-02 | AKR1B10 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 5.987E-03 | 1.793E-02 | AKR1B10 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.977E-03 | 1.793E-02 | MAOA |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00260 | Glycine, serine and threonine metabolism | 7.977E-03 | 1.793E-02 | MAOA |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 6.385E-03 | 1.793E-02 | AKR1B10 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 9.765E-03 | 1.793E-02 | MAOA |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00330 | Arginine and proline metabolism | 9.963E-03 | 1.793E-02 | MAOA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
